Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

Charlotte Costentin 1, * Richard Layese 2 Valérie Bourcier 3 Carole Cagnot 4 Patrick Marcellin 5 Dominique Guyader 6 Stanislas Pol 7, 8, 9 Dominique Larrey 10, 11 Victor de Ledinghen 12 Denis Ouzan 13 Fabien Zoulim 14 Dominique Roulot 15 Albert Tran 16 Jean-Pierre Bronowicki 17 Jean-Pierre Zarski 18, 19 Ghassan Riachi 20 Paul Calès 21 Jean-Marie Péron 22, 23 Laurent Alric 24 Marc Bourlière 25 Philippe Mathurin 26 Jean-Frédéric Blanc 27, 12 Armand Abergel 28, 29, 30 Lawrence Serfaty 31 Ariane Mallat 32, 33, 34 Jean-Didier Grangé 35 Pierre Attali 36 Yannick Bacq 37 Claire Wartelle 38 Thong Dao 39 Dominique Thabut 40 Christophe Pilette 41 Christine Silvain 42 Christos Christidis 43 Eric Nguyen-Khac 44 Brigitte Bernard-Chabert 45 David Zucman 46 Vincent Di Martino 47 Angela Sutton 3 Eric Letouzé 48 Sandrine Imbeaud 48 Jessica Zucman-Rossi 48, 49, 50, 51 Etienne Audureau 52, 2 Françoise Roudot-Thoraval 52 Pierre Nahon 48
* Auteur correspondant
1 CHU Henri Mondor
2 CEpiA - Clinical Epidemiology and Ageing : Geriatrie Soins Primaires et Santé Publique
3 Hôpital Jean Verdier [AP-HP]
4 ANRS France Recherche Nord & sud Sida-hiv hépatites
5 Service d’Hépatologie [Hôpital Beaujon]
6 NuMeCan - Nutrition, Métabolismes et Cancer
7 Inserm U1223 - Physiopathologie du système immunitaire
8 Département d'hépatologie [CHU Cochin]
9 UPD5 - Université Paris Descartes - Paris 5
10 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)
11 Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi]
12 Hôpital Haut-Lévêque [CHU Bordeaux]
13 Institut Arnault Tzanck
14 HCL - Hospices Civils de Lyon
15 Service de Gastro-entérologie [Avicenne]
16 C3M - Centre méditerranéen de médecine moléculaire
17 Service d'Hépato-gastro-entérologie [CHRU Nancy]
18 Département d'hépato-gastroentérologie
19 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
20 Service d'Hépato-Gastroentérologie [CHU Rouen]
21 HIFIH - Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques
22 CHU Toulouse [Toulouse]
23 UT3 - Université Toulouse III - Paul Sabatier
24 PHARMA-DEV - Pharmacochimie et Biologie pour le Développement
25 Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille]
26 Hôpital Claude Huriez [Lille]
27 Physiopathologie du cancer du foie
28 IP - Institut Pascal
29 UCA [2017-2020] - Université Clermont Auvergne [2017-2020]
30 CNRS - Centre National de la Recherche Scientifique
31 Service d'Hépato-gastro-entérologie [CHU Saint-Antoine]
32 UMR INSERM U955
33 UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12
34 Inserm U955 - Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18)
IMRB - Institut Mondor de Recherche Biomédicale
35 CHU Tenon [AP-HP]
36 Onxeo S.A.
37 Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours]
38 CHIAP - Centre Hospitalier d'Aix en Provence [Aix-en-Provence]
39 Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen]
40 Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière]
41 Centre Hospitalier Le Mans (CH Le Mans)
42 CHU Poitiers - Centre hospitalier universitaire de Poitiers
43 Hellenic Open University [Patras]
44 Service d'Hépato Gastroenterologie [CHU Amiens-Picardie]
45 CHU Reims - Centre Hospitalier Universitaire de Reims
46 Hôpital Foch [Suresnes]
47 Service d'Hépatologie [CHRU Besançon]
48 U1162 - Génomique Fonctionnelle des Tumeurs Solides
49 IUH - Institut Universitaire d'Hématologie
50 UP13 - Université Paris 13
51 HEGP - Hôpital Européen Georges Pompidou [APHP]
52 Service de santé publique [Mondor]
Abstract : Background & aims - Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis who developed HCC. Methods - We collected data from the prospective ANRS CO12 CirVir study, from March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis and no previous liver complications who were undergoing surveillance for HCC at 35 centers in France. Only 216 patients who developed HCC during the follow-up period were included in the analysis. Patients were considered to be compliant with surveillance guidelines if the time between their last surveillance image evaluation and diagnosis of HCC were fewer than 7 months and noncompliant if this time was 7 months or longer. Results - HCC was detected in 216 patients, at a median follow-up time of 59.7 months. Of these patients, 140 (80.5%) were Barcelona Clinic Liver Cancer stage 0/A, 135 (69.9%) received first-line curative treatment (15 underwent transplantation, 29 underwent resection, 89 received percutaneous ablation, and 2 received resection and percutaneous ablation), and 129 (60.0%) were compliant with surveillance guidelines. Seventy-nine of the patients with HCC died; 49 deaths were associated with tumor progression. After lead-time adjustment, overall survival (OS) time was longer in patients compliant with surveillance guidelines (median OS time, 53.2 months) than noncompliant patients (median OS time, 25.4 months) (P = .0107); this difference remained significant even when we changed lead time assumptions. In multivariate analysis adjusted for a propensity score, compliance with HCC surveillance guidelines was associated with low tumor burden, allocation of curative treatment, and increased OS time compared with noncompliance (hazard ratio for OS, 2.19; 95% confidence interval, 1.16-4.14; P = .0150). Conclusions - In an analysis of data from the ANRS CO12 CirVir cohort, we associated compliance with HCC surveillance guidelines (fewer than 7 months between image evaluations) with early diagnosis, allocation of curative treatment, and longer adjusted OS of patients with hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis and a diagnosis of HCC.
Keywords : Antiviral Agents Carcinoma Hepatocellular Early Detection of Cancer Hepacivirus Guideline Adherence France Follow-Up Studies Female Multivariate Analysis Practice Guidelines as Topic Prospective Studies hepatitis B virus Humans Kaplan-Meier Estimate Liver Liver Cirrhosis Liver neoplasms Male Middle Aged Aged
Type de document :
Article dans une revue
Liste complète des métadonnées
https://hal.univ-angers.fr/hal-02648451
Contributeur : Okina Univ Angers Connectez-vous pour contacter le contributeur
Soumis le : vendredi 29 mai 2020 - 09:36:03
Dernière modification le : vendredi 20 mai 2022 - 11:06:41

Identifiants

Collections

UNIV-ANGERS | UNIV-TLSE3 | HCL | U823 | IMRB | INSTITUT_PASCAL | UPEC-UPEM | UPEC | UNIV-RENNES1 | NUMECAN | COMUE-NORMANDIE | UNIV-MONTPELLIER | UNIV-COTEDAZUR | UNIROUEN | UNIV-AMU | UNICAEN | CNRS | NUMECAN-EXPRES | SORBONNE-PARIS-NORD | UNIV-PARIS13 | PRES_CLERMONT | BS | UNIV-PARIS5 | UNIV-PARIS7 | HIFIH | UR1-UFR-SVE | UNIV-RENNES | USPC | SORBONNE-UNIVERSITE | UNIV-PARIS | SU-MEDECINE | UR1-BIO-SA | PASTEUR | PHARMA-DEV | IRD | UGA | C3M | INC-CNRS | ENVA

Citation

Charlotte Costentin, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, et al.. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, WB Saunders, 2018, 155 (2), pp.431-442.e10. ⟨10.1053/j.gastro.2018.04.027⟩. ⟨hal-02648451⟩

Exporter

BibTeX TEI DC DCterms EndNote Datacite

Partager

Métriques

Consultations de la notice

137